Verona Pharma PLC ADR (VRNA NASDAQ) stock market data APIs
$106.99
0(0%)
as of October 7, 2025
Try our APIs with
free plan!
Verona Pharma PLC ADR Financial Data Overview
Price chart is built with
Anychart
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
Prev. Close
106.99
Open
106.99
High
106.99
Low
106.99
52 wk Range
31.6-106.93
Market Cap
9 085 M
Shares Outstanding
84 979 K
Revenue
222 M
EPS
-0.005
Beta
0.052
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Verona Pharma PLC ADR (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Verona Pharma PLC ADR data using free add-ons & libraries
Get Verona Pharma PLC ADR Fundamental Data
Verona Pharma PLC ADR Fundamental data includes:
- Net Revenue: 222 M
- EBITDA: -52 737 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: 0.029
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Verona Pharma PLC ADR News
New
Merck Completes $10B Acquisition of Verona Pharma, Adds COPD Drug Ohtuvayre
Merck & Co. Inc. (NYSE:MRK) is one of the best growth stocks to buy now. On October 7, Merck & Co. announced the completion of its acquisition of Verona Pharma (NASDAQ:VRNA). Verona Pharma is now a wh...
Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend
Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest.Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion ...
VRNA Quantitative Stock Analysis
Below is Validea's guru fundamental report for VERONA PHARMA PLC - ADR (VRNA). Of the 22 guru strategies we follow, VRNA rates highest using our Quantitative Momentum Investor model based on the publ...
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
Merck’s MRK shares have risen almost 13% in the past week as Pfizer’s PFE landmark deal with the Trump administration to lower drug costs eased investor concerns over pricing and tariffs in the ph...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
